Annual Meeting

Cracking foods’ anti-cancer properties

Intrigued first by tamarind’s antibacterial ability, researcher in Puerto Rico next sets her sights on legumes as she investigates ways to defeat triple-negative inflammatory breast cancer

What if patients with breast cancer could consume legumes, such as soy sprouts, and greatly reduce the chances of their cancer metastasizing? This is one of the questions researchers at the University of Puerto Rico at Río Piedras are interested in answering, and their work already has yielded some intriguing findings, which will be presented Tuesday in Philadelphia at the annual meeting of the American Society for Biochemistry and Molecular Biology. 

Courtesy of Keishla M. Rodríguez–Mártir
Keishla M. Rodríguez–Mártir works with her cancer cell lines.

Graduate student Keishla M. Rodríguez–Mártir is working on her dissertation in the lab of Esther Peterson–Peguero. Rodríguez–Mártir is studying coumestrol, a phytoestrogen similar in structure to estrogen and found in foods such as soy, alfalfa, clover and Kala chala (a type of chickpea), among others. She aims to determine if coumestrol has anti-cancer effects in triple-negative inflammatory breast cancer, or TN-IBC, cell lines as it does in other cancer cell lines. 

Rodríguez–Mártir’s dissertation research idea sprang from a project she was involved in as an undergraduate student at the University of Puerto Rico at Aguadilla, where she was assessing tamarind’s antibacterial properties. 

“(This property) always called my attention — how something that we can buy at the grocery store works against bacterial infections,” she said. “This was something I was interested in exploring. (I wondered if) people receiving chemotherapy could supplement their treatment with something natural and accessible to them.” 

Triple-negative breast cancer does not have estrogen or progesterone receptors, and it has low-to-no HER2 protein production. As a result, it cannot be treated with hormone or HER2-targeted therapy. 

Molecular structure of coumestrol, a phytoestrogen with a structure similar to estrogen.

The inflammatory aspect of TN-IBC further complicates clinical outcomes, because it does not present with lumps but instead creates redness and inflammation and thus may not show up on a mammogram. This presentation causes doctors to explore other possible noncancerous causes first, which ultimately delays cancer detection. By the time it is diagnosed, it usually has metastasized and consequently results in a worse prognosis for the patient. 

Rodríguez–Mártir dived into the scientific literature and came upon studies of phytoestrogens and their relationship to reduced risk of death and disease recurrence in women with breast cancer. Specifically, she focused on coumestrol because published data suggest that it has cytotoxic effects against triple-negative cell lines, but it had not been studied yet in the context of triple-negative inflammatory breast cancer. 

Rodríguez–Mártir first sought to test the hypothesis that coumestrol could have cytotoxic effects on TN-IBC cell lines by using a 2D cell-culture model of TN-IBC cells. She conducted dose-response assays with coumestrol to determine half-maximal inhibitory concentration, followed by cell viability, migration and invasion assays, complemented by assessment of downstream signaling following coumestrol treatment. 

She determined that coumestrol decreases cell viability, migration and invasion in TN-IBC cell lines. She also demonstrated that coumestrol downregulates pro-oncogenic signaling and upregulates genes involved in breast cancer suppression. 

“Studies have determined that Asian and vegetarian women with high phytoestrogen dietary consumption have a low rate of incidence of breast cancer. Further, Chinese women who have breast cancer and consume phytoestrogens have a significantly lower mortality rate than their counterparts who do not,” she said. “I would like to identify a natural compound that (patients) can easily consume to support their therapy.” 

Keishla M. Rodríguez–Mártir will present this research at 1:10 p.m. Tuesday, April 5, in Exhibit/Poster Hall A–B, Pennsylvania Convention Center (Poster Board Number A310) (abstract). In addition, the next step in her project, 3D models using matrigels, will be presented at the same time by her undergraduate colleague Ayeisha Colón–Ortíz (abstract).

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
O. Hecmarie  Meléndez-Fernández

O. Hecmarie Meléndez-Fernández is a Ph.D. candidate in neuroscience at West Virginia University.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Differences in pili structure modulate bacterial behavior
Journal News

Differences in pili structure modulate bacterial behavior

April 14, 2026

Researchers demonstrate how small changes in the structure of hair-like protein appendages can affect the behavior of Acinetobacter bacteria.

Cholesterol regulatory genes predict liver transplant outcomes
Journal News

Cholesterol regulatory genes predict liver transplant outcomes

April 10, 2026

Researchers identify a link between cholesterol-regulating genes and liver transplant success, which could improve donor screening and patient outcomes.

Lipid signatures for a rare neurological disorder
Journal News

Lipid signatures for a rare neurological disorder

April 10, 2026

Researchers find distinct lipid patterns linked to a rare autoimmune neurological disorder, offering hope for effective targeted therapies for patients.

Disease-linked mutations disrupt protein phase behavior
Journal News

Disease-linked mutations disrupt protein phase behavior

April 9, 2026

Researchers find that pathogenic missense mutations are enriched threefold in phrase-separating intrinsically disordered regions of proteins.

The dual role of asprosin in chronic fatty liver disease
Journal News

The dual role of asprosin in chronic fatty liver disease

April 8, 2026

Researchers uncover a hormone called asprosin that may serve as a potential biomarker for the diagnosis of chronic fatty liver disease and monitoring disease progression.

Novel inhibitor targets RAS-driven cancers
Journal News

Novel inhibitor targets RAS-driven cancers

April 7, 2026

Researchers in Louisville identify a small-molecule drug that blocks RALGEF signaling downstream of mutant RAS. The compound suppresses tumor growth with low toxicity, revealing a new therapeutic strategy for RAS-driven malignancies.